|Bid||2.9300 x 800|
|Ask||2.9800 x 1400|
|Day's Range||2.9200 - 2.9900|
|52 Week Range||1.6000 - 3.9500|
|Beta (3Y Monthly)||2.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It hasn't been the best quarter for Biomerica, Inc. (NASDAQ:BMRA) shareholders, since the share price has fallen 11...
The big shareholder groups in Biomerica, Inc. (NASDAQ:BMRA) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies...
Biomerica (BMRA) reported financial results for their fiscal 2019 third quarter ending February 28, 2019. Revenue has decreased each of the first three quarters of 2019 as compared to the respective prior-year periods and through the first nine months, is down 9% from 2018. Revenue through the first nine months from each of three most significant territories is down from last year.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching Biomerica, Inc. (NASDAQ:BMRA) might want to consider theRead More...
How far off is Biomerica, Inc. (NASDAQ:BMRA) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly Read More...
Results of an n=97 randomized, investigator-blinded food-exclusion study showed that Biomerica’s (BMRA) first-generation ELISA immunoglobulin G (IgG) antibody assay was able to significantly reduce ulcerative colitis symptoms and improve participants’ quality of life. In addition, this study assessed BMRA’s test in individuals with ulcerative colitis (UC) – while InFoods has been developed primarily to determine optimal food exclusion diets for people with irritable bowel syndrome.
Every investor in Biomerica Inc (NASDAQ:BMRA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...
Biomerica (BMRA) reported financial results for their fiscal 2019 first quarter ending August 31, 2018. The weakness related almost entirely to Europe and the U.S., which were both down double-digit percentages from the year-earlier period. Fortunately Asia, which accounts for ~50% of total revenue saw solid gains from both comparable periods, limiting the yoy total revenue slide and pushing it into positive territory sequentially.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Biomerica Inc (NASDAQ:BMRA), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...
Biomerica (BMRA) reported financial results for their fiscal 2018 fourth quarter ending May 31, 2018. While our model had revenue inching up 6% for the full-year reflecting an expectation that rebounding sales in Asia would more than offset ongoing softness in both Europe and the U.S., that was far from the case. Instead, the nearly across-the-board (Latin America was the sole bright spot) weakness in Q4, which most notably included a 42% yoy contraction in Asia, resulted in annual sales falling almost 4%.